Hydroxychloroquine Decreases Th17-related Cytokines in Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients

Overview

Journal Clinics (Sao Paulo)

Publisher Elsevier

Specialty General Medicine

Date 2013 Jun 20

PMID 23778483

Citations 68

Authors

Juliana Cruz da Silva

Henrique Ataide Mariz

Laurindo Ferreira da Rocha Jr

Priscilla Stela Santana de Oliveira

Andrea Tavares Dantas

Angela Luzia Branco Pinto Duarte

Ivan da Rocha Pitta

Suely Lins Galdino

Maira Galdino da Rocha Pitta

Affiliations

Soon will be listed here.

Abstract

Objectives: Hydroxychloroquine is an antimalarial agent that has been used in systemic lupus erythematosus and rheumatoid arthritis treatment for many years. Recently, novel mechanisms of action have been proposed, thereby broadening the therapeutic perspective of this medication. The purpose of this study was to evaluate the immunomodulatory activity of hydroxychloroquine in T helper 17 (Th17) cytokines in healthy individuals and patients.

Methods: Eighteen female patients with systemic lupus erythematosus (mean age 39.0±12.9 years) and 13 female patients with rheumatoid arthritis (mean age 51.5±7.7 years) were recruited from Universidade Federal de Pernambuco-Brazil. The patients were included after fulfilling four classification criteria for systemic lupus erythematosus or rheumatoid arthritis from the American College of Rheumatology. After being stimulated with phorbol 12-myristate 13-acetate and ionomycin in the absence or presence of different concentrations of hydroxychloroquine, the interleukin 6, 17 and 22 levels were quantified with an enzyme-linked immunosorbent assay in culture supernatants of peripheral blood mononuclear cells from healthy individuals and patients.

Results: We demonstrated that in peripheral blood mononuclear cells from healthy volunteers and in systemic lupus erythematosus and rheumatoid arthritis patients, there was a significant reduction in the IL-6, IL-17 and IL-22 supernatant levels after adding hydroxychloroquine. CONCLUSIONS Our in vitro results demonstrated that hydroxychloroquine inhibits IL-6, IL-17 and IL-22 production and contributes to a better understanding of the mechanism of action of this medication.

Citing Articles

Target in Sight: A Comprehensive Review of Hydroxychloroquine-Induced Bull's Eye Maculopathy.

Snow Z, Seely K, Barrett S, Pecha J, Goldhardt R Curr Ophthalmol Rep. 2024; 12(3):38-48.

PMID: 39371107 PMC: 11452169. DOI: 10.1007/s40135-024-00321-6.

Treating Cardiovascular Disease in the Inflammatory Setting of Rheumatoid Arthritis: An Ongoing Challenge.

Godbole S, Solomon J, Johnson M, Srivastava A, Carsons S, Belilos E Biomedicines. 2024; 12(7).

PMID: 39062180 PMC: 11275112. DOI: 10.3390/biomedicines12071608.

Multiplex array analysis of circulating cytokines and chemokines in COVID-19 patients during the first wave of the SARS-CoV-2 pandemic in Milan, Italy.

Calvo-Alvarez E, DAlessandro S, Zanotta N, Basilico N, Parapini S, Signorini L BMC Immunol. 2024; 25(1):49.

PMID: 39061002 PMC: 11282750. DOI: 10.1186/s12865-024-00641-z.

Advancements on the impact of hydroxychloroquine in systemic lupus erythematosus.

Peng-Cheng L, Meng-Na L, Jian-Bin L, Shu-Jiao Y, Wu R Heliyon. 2024; 10(9):e30393.

PMID: 38711668 PMC: 11070867. DOI: 10.1016/j.heliyon.2024.e30393.

Synthesis and and Anti-inflammatory Activity of New Thiazolidinedione-quinoline Derivatives.

da Silva S, da Silva Moura J, Branco Junior J, de Moraes Gomes P, de Paula S, Viana D Curr Top Med Chem. 2024; 24(14):1264-1277.

PMID: 38523516 DOI: 10.2174/0115680266295582240318060802.

References

Wozniacka A, Lesiak A, Boncela J, Smolarczyk K, McCauliffe D, Sysa-Jedrzejowska A . The influence of antimalarial treatment on IL-1beta, IL-6 and TNF-alpha mRNA expression on UVB-irradiated skin in systemic lupus erythematosus. Br J Dermatol. 2008; 159(5):1124-30. DOI: 10.1111/j.1365-2133.2008.08804.x. View

Molad Y, Gorshtein A, Wysenbeek A, Guedj D, Majadla R, Weinberger A . Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort. Lupus. 2002; 11(6):356-61. DOI: 10.1191/0961203302lu203ra. View

Ohkuma S, Poole B . Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc Natl Acad Sci U S A. 1978; 75(7):3327-31. PMC: 392768. DOI: 10.1073/pnas.75.7.3327. View

Yang J, Chu Y, Yang X, Gao D, Zhu L, Yang X . Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum. 2009; 60(5):1472-83. DOI: 10.1002/art.24499. View

da Rocha Jr L, Duarte A, Dantas A, Mariz H, da Rocha Pitta I, Lins Galdino S . Increased serum interleukin 22 in patients with rheumatoid arthritis and correlation with disease activity. J Rheumatol. 2012; 39(7):1320-5. DOI: 10.3899/jrheum.111027. View

Chabaud M, Durand J, Buchs N, Fossiez F, Page G, Frappart L . Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum. 1999; 42(5):963-70. DOI: 10.1002/1529-0131(199905)42:5<963::AID-ANR15>3.0.CO;2-E. View

Hirota K, Yoshitomi H, Hashimoto M, Maeda S, Teradaira S, Sugimoto N . Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J Exp Med. 2007; 204(12):2803-12. PMC: 2118525. DOI: 10.1084/jem.20071397. View

van den Borne B, Dijkmans B, de Rooij H, le Cessie S, Verweij C . Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells. J Rheumatol. 1997; 24(1):55-60. View

Tan E, Cohen A, Fries J, MASI A, McShane D, Rothfield N . The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982; 25(11):1271-7. DOI: 10.1002/art.1780251101. View

10.

Kyburz D, Brentano F, Gay S . Mode of action of hydroxychloroquine in RA-evidence of an inhibitory effect on toll-like receptor signaling. Nat Clin Pract Rheumatol. 2006; 2(9):458-9. DOI: 10.1038/ncprheum0292. View

11.

Koenders M, Lubberts E, Oppers-Walgreen B, van den Bersselaar L, Helsen M, Di Padova F . Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am J Pathol. 2005; 167(1):141-9. PMC: 1603454. DOI: 10.1016/S0002-9440(10)62961-6. View

12.

Crispin J, Tsokos G . Interleukin-17-producing T cells in lupus. Curr Opin Rheumatol. 2010; 22(5):499-503. DOI: 10.1097/BOR.0b013e32833c62b0. View

13.

Katz S, Russell A . Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action. Curr Opin Rheumatol. 2011; 23(3):278-81. DOI: 10.1097/BOR.0b013e32834456bf. View

14.

Wallace D, Gudsoorkar V, Weisman M, Venuturupalli S . New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat Rev Rheumatol. 2012; 8(9):522-33. DOI: 10.1038/nrrheum.2012.106. View

15.

ZIEGLER H, UNANUE E . Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells. Proc Natl Acad Sci U S A. 1982; 79(1):175-8. PMC: 345685. DOI: 10.1073/pnas.79.1.175. View

16.

Dong G, Ye R, Shi W, Liu S, Wang T, Yang X . IL-17 induces autoantibody overproduction and peripheral blood mononuclear cell overexpression of IL-6 in lupus nephritis patients. Chin Med J (Engl). 2003; 116(4):543-8. View

17.

Roman M, Shanker B, Davis A, Lockshin M, Sammaritano L, Simantov R . Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003; 349(25):2399-406. DOI: 10.1056/NEJMoa035471. View

18.

Wasko M, Hubert H, Lingala V, Elliott J, Luggen M, Fries J . Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA. 2007; 298(2):187-93. DOI: 10.1001/jama.298.2.187. View

19.

Alarcon G, McGwin G, Bertoli A, Fessler B, Calvo-Alen J, Bastian H . Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis. 2007; 66(9):1168-72. PMC: 1955128. DOI: 10.1136/ard.2006.068676. View

20.

Barrat F, Meeker T, Gregorio J, Chan J, Uematsu S, Akira S . Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med. 2005; 202(8):1131-9. PMC: 2213213. DOI: 10.1084/jem.20050914. View